Zai Lab
ZLAB
About: Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Employees: 1,844
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33.2% more ownership
Funds ownership: 5.15% [Q1] → 38.35% (+33.2%) [Q2]
8% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 36
3% less funds holding
Funds holding: 158 [Q1] → 154 (-4) [Q2]
17% less call options, than puts
Call options by funds: $6.06M | Put options by funds: $7.27M
19% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 59
24% less capital invested
Capital invested by funds: $1.97B [Q1] → $1.49B (-$479M) [Q2]
29% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 5 (-2) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Citigroup
Yigal Nochomovitz
|
$69
|
Buy
Maintained
|
11 Aug 2025 |
|
Leerink Partners
Jonathan Chang
|
$75
|
Outperform
Maintained
|
30 Jun 2025 |
Financial journalist opinion
Based on 7 articles about ZLAB published over the past 30 days
